Shannon Parisotto Sells 5,046 Shares of Charles River Laboratories International (NYSE:CRL) Stock

Charles River Laboratories International, Inc. (NYSE:CRL) EVP Shannon Parisotto sold 5,046 shares of the stock in a transaction dated Wednesday, August 5th. The shares were sold at an average price of $263.00, for a total value of $1,327,098.00. Following the completion of the transaction, the executive vice president directly owned 4,807 shares in the company, valued at $1,264,241. The trade was a 51.21% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Charles River Laboratories International Price Performance

Charles River Laboratories International stock opened at $266.95 on Friday. The company has a current ratio of 1.35, a quick ratio of 1.03 and a debt-to-equity ratio of 0.92. The firm has a market capitalization of $12.74 billion, a P/E ratio of -55.04, a PEG ratio of 2.92 and a beta of 1.38. The business has a 50-day moving average of $214.85 and a 200-day moving average of $189.25. Charles River Laboratories International, Inc. has a 1 year low of $144.26 and a 1 year high of $268.00.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings results on Wednesday, August 5th. The medical research company reported $3.02 earnings per share for the quarter, beating analysts’ consensus estimates of $2.77 by $0.25. The business had revenue of $1 billion for the quarter, compared to the consensus estimate of $980.53 million. Charles River Laboratories International had a negative net margin of 5.96% and a positive return on equity of 15.75%. Charles River Laboratories International’s revenue for the quarter was down 2.7% on a year-over-year basis. During the same period last year, the company posted $3.12 EPS. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. On average, equities analysts anticipate that Charles River Laboratories International, Inc. will post 11.17 EPS for the current year.

Hedge Funds Weigh In On Charles River Laboratories International

A number of large investors have recently added to or reduced their stakes in the company. Los Angeles Capital Management LLC acquired a new position in shares of Charles River Laboratories International during the fourth quarter worth about $42,000. Sfam LLC acquired a new stake in Charles River Laboratories International in the 4th quarter valued at approximately $43,000. Activest Wealth Management lifted its stake in Charles River Laboratories International by 10,900.0% in the 4th quarter. Activest Wealth Management now owns 220 shares of the medical research company’s stock valued at $44,000 after acquiring an additional 218 shares in the last quarter. Elyxium Wealth LLC acquired a new position in Charles River Laboratories International during the 4th quarter worth approximately $46,000. Finally, Geneos Wealth Management Inc. grew its stake in shares of Charles River Laboratories International by 98.0% during the 2nd quarter. Geneos Wealth Management Inc. now owns 293 shares of the medical research company’s stock worth $44,000 after acquiring an additional 145 shares in the last quarter. Institutional investors own 98.91% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the stock. Weiss Ratings upgraded shares of Charles River Laboratories International from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, July 1st. Robert W. Baird set a $291.00 target price on Charles River Laboratories International in a research note on Thursday. BNP Paribas Exane set a $250.00 price target on Charles River Laboratories International in a report on Wednesday, July 1st. Evercore reaffirmed an “outperform” rating on shares of Charles River Laboratories International in a research report on Wednesday. Finally, Citigroup reiterated a “buy” rating on shares of Charles River Laboratories International in a research report on Wednesday, July 8th. Twelve equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Charles River Laboratories International has an average rating of “Moderate Buy” and a consensus target price of $246.69.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.